Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Comparative Effectiveness Funding In Stimulus Bill Raises Some Red Flags

Executive Summary

Industry observers see red flags in how House Democrats have structured the language related to comparative effectiveness in the economic stimulus bill, with questions on how the money will be spent as well as its potential to leave the door open for cost-effectiveness comparisons of medical products

You may also be interested in...



PCORI’s Slow Start On Comparative Research May Protect It From Political Heat

The Patient-Centered Outcomes Research Institute’s slow ramp-up to being in a position to fund comparative research projects may actually help it survive a heated political environment in an election year.

Comparative Effectiveness “Infrastructure” Could Get Discretionary Funding

The $400 million discretionary fund for comparative effectiveness research to be administered by the secretary of Health and Human Services might not be used for research at all

Comparative Effectiveness “Infrastructure” Could Get Discretionary Funding

The $400 million discretionary fund for comparative effectiveness research to be administered by the secretary of Health and Human Services might not be used for research at all

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS050583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel